[의학바이오게시판] Samsung Seoul Hospital ‘Online Training for Critical Care Nursing’, etc. : Dong-A Science

On the 14th, Samsung Medical Center Partners Center and the Nursing Education Team held an ‘Intensive Care Nursing Online Education’ under the theme of ‘Understanding and Managing Ventilators’. Provided by Samsung Seoul Hospital

■ Samsung Medical Center Partners Center and Nursing Education Team held ‘Online Training for Critical Care Nursing’ under the theme of ‘Understanding and Managing Ventilators’ on the 14th. On the 21st, ‘diagnosing and treating renal failure (focused on renal replacement therapy)’, and the same content in August. Currently, 1,700 people from 87 institutions have applied. Compared to the number of people who participated in offline training before Corona, the number of people participating in cooperative institutions nationwide has dramatically increased as it is conducted online. For inquiries, please contact the Samsung Seoul Hospital Partners Center (02-3410-3031).

■ National Cancer Center Rare Cancer Center Director Hyungwi Kang published an English book ‘Clinical Atlas of 3D Printing Bone Reconstruction’ by Springer Publishing Company. 3D printing bone reconstruction is a surgical method that 3D designs, manufactures, and implants the shape of bone needed for patients with bone loss due to disease or accident. Unlike other 3D printing medical books, which are mostly computer and mechanical engineering content, this book is mainly composed of various clinical cases.

■ Hallym University Sacred Heart Hospital held the ‘2021 Hallym Innovation Strategy Workshop’ at Ilsong Culture Hall on the 5th floor of the 2nd Annex. Analyze current medical policies, foster smart hospitals for medical service innovation, improve medical quality through analysis of medical institution evaluation systems, analyze crises of domestic medical institutions and respond to changes in external environment, and work with local communities tailored to the non-face-to-face era It proceeded in the order of a plan to strengthen the bonds of

■ Celltrion received emergency use approval from the Indonesian Ministry of Food and Drug Safety on the 17th for ‘Rekkorona (ingredient name: Legdanvirab)’, a treatment for COVID-19 antibody developed by Celltrion. Rekkona will be used urgently for mild and moderately ill patients in the high-risk group of adults who have been confirmed with COVID-19. Celltrion recently confirmed the neutralizing ability of Reckrona as a result of animal tests on the delta mutant virus, so it is expected that Reckrona will be of great help in preventing the spread of Corona 19 in Indonesia.

.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.